Research Progress on Sesquiterpenes from the Genus Ainsliaea

Molecules. 2024 Nov 20;29(22):5483. doi: 10.3390/molecules29225483.

Abstract

Sesquiterpenes constitute the principal components of the genus Ainsliaea, encompassing guaiane, germacrane, eudesmane, and polymer sesquiterpene lactones types. These secondary metabolites exhibit diverse pharmacological activities, including antitumor, antibacterial, anti-inflammatory, antiviral, antioxidant, hepatoprotective, and neuroprotective effects. Through a comprehensive literature search of the Web of Science, PubMed, SciFinder, and CNKI databases, it was discovered that there are as many as 145 main sesquiterpenoids in the genus Ainsliaea. However, the nuclear magnetic resonance (NMR) data for the sesquiterpenes in this genus have not been systematically compiled and summarized. Therefore, this review aims to highlight the chemical structures, NMR data, and pharmacological activities of sesquiterpenes in Ainsliaea. By meticulously analyzing published scholarly literature, our goal is to provide a solid foundation for further exploration of new sesquiterpenes and extensive utilization of this genus.

Keywords: Ainsliaea; nuclear magnetic resonance (NMR); sesquiterpenes; structure analysis.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / chemistry
  • Antioxidants / pharmacology
  • Asteraceae / chemistry
  • Humans
  • Molecular Structure
  • Plant Extracts / chemistry
  • Plant Extracts / pharmacology
  • Sesquiterpenes* / chemistry
  • Sesquiterpenes* / pharmacology

Substances

  • Sesquiterpenes
  • Antioxidants
  • Plant Extracts
  • Anti-Inflammatory Agents

Grants and funding

This research was funded by the National Natural Science Foundation of China (No. 82160672), the General Project of Ningxia Natural Science Foundation (No. 2024AAC03172), and the Scientific Research Start-up project for Recruitment Talents of North Minzu University in 2021 (No. 2021KYQD35).